Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anvumetostat in MTAP-Deleted Advanced NSCLC
NCT06593522Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of anvumetostat in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Dec 2024; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06593522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06593522.